Wesley Huang

Wesley Huang

Auto-generated profile, based on publicly available information

Wesley Huang

Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in Cancer Cell
Verified
Journal Article
Closed access
HBHannah N. Bell
Hannah N. Bell
RRRyan J. Rebernick
Ryan J. Rebernick
JGJoshua Goyert
Joshua Goyert
RSRashi Singhal
Rashi Singhal
MKMiljan Kuljanin
Miljan Kuljanin
YSYatrik Shah
Yatrik Shah

30 June 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
NCNaiara Santana Codina
Naiara Santana Codina
MRMaria Quiles del Rey
Maria Quiles del Rey
KKKevin S. Kapner
Kevin S. Kapner
HZHuan Zhang
Huan Zhang
AGAjami Gikandi
Ajami Gikandi
JMJoe Mancias
Joe Mancias
Pancreatic ductal adenocarcinomas (PDAC) depend on autophagy for survival; however, the metabolic substrates that autophagy provides to drive PDAC progression are unclear. Ferritin, the cellular iron storage complex, is targeted for lysosomal degradation (ferritinophagy) by the selective autophagy adaptor NCOA4, resulting in release of iron for cellular utilization. Using patient-derived and murine models of PDAC, we demonstrate that ferritinophagy is upregulated in PDAC to sustain iron availability, thereby promoting tumor progression. Quantitative proteomics reveals that ferritinophagy fuels iron–sulfur cluster protein synthesis to support mitochondrial homeostasis. Targeting NCOA4 leads to tumor growth delay and prolonged survival but with the development of compensatory iron acquisition pathways. Finally, enhanced ferritinophagy accelerates PDAC tumorigenesis, and an elevated ferritinophagy expression signature predicts for poor prognosis in patients with PDAC. Together, our data reveal that the maintenance of iron homeostasis is a critical function of PDAC autophagy, and we define NCOA4-mediated ferritinophagy as a therapeutic target in PDAC. Significance: Autophagy and iron metabolism are metabolic dependencies in PDAC. However, targeted therapies for these pathways are lacking. We identify NCOA4-mediated selective autophagy of ferritin (“ferritinophagy”) as upregulated in PDAC. Ferritinophagy supports PDAC iron metabolism and thereby tumor progression and represents a new therapeutic target in PDAC. See related commentary by Jain and Amaravadi, p. 2023. See related article by Ravichandran et al., p. 2198. This article is highlighted in the In This Issue feature, p. 2007

26 June 2025 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
WHWesley Huang
Wesley Huang
YZYuezhong Zhang
Yuezhong Zhang
NDNupur Das
Nupur Das
SSSumeet Solanki
Sumeet Solanki
CJChesta Jain
Chesta Jain
YSYatrik Shah
Yatrik Shah

18 October 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
DMDavid Van Mater
David Van Mater
EXEric Xu
Eric Xu
ARAnupama Reddy
Anupama Reddy
LALeonor Añó
Leonor Añó
MSMohit Sachdeva
Mohit Sachdeva
DKDavid G. Kirsch
David G. Kirsch
Cancer results from the accumulation of genetic mutations in a susceptible cell of origin. We and others have also shown that injury promotes sarcoma development, but how injury cooperates with genetic mutations at the earliest stages of tumor formation is not known. Here, we utilized dual recombinase technology to dissect the complex interplay of the timing of Kras G12D activation, p53 deletion, and muscle injury in sarcomagenesis using a primary mouse model of soft tissue sarcoma. When mutations in oncogenic Kras and p53 are separated by 3 weeks, few sarcomas develop without injury. However, the transformation potential of these tumor-initiating cells can be unmasked by muscle injury. In the absence of Kras mutations, injury of the muscle with global deletion of p53 results in sarcomas with amplification of chromosomal regions encompassing the Met or Yap1 gene. These findings demonstrate a complex interplay between the timing of genetic mutations and perturbations in the tumor microenvironment, which provides insight into the earliest stages of sarcoma development.

21 January 2024 in The Journal of Nutrition
Verified
Journal Article
Closed access
WHWesley Huang
Wesley Huang
NDNupur Das
Nupur Das
MRMegan D Radyk
Megan D Radyk
TKTheresa Keeley
Theresa Keeley
MQMiguel Quiros
Miguel Quiros
YSYatrik Shah
Yatrik Shah

27 July 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RDRebecca Dodd
Rebecca Dodd
ASAmanda Scherer
Amanda Scherer
WHWesley Huang
Wesley Huang
GMGavin R. McGivney
Gavin R. McGivney
WGWade Gutierrez
Wade Gutierrez
DKDavid G. Kirsch
David G. Kirsch
Purpose: Nanoparticle-encapsulated drug formulations can improve responses to conventional chemotherapy by increasing drug retention within the tumor and by promoting a more effective antitumor immune response than free drug. New drug delivery modalities are needed in sarcomas because they are often chemoresistant cancers, but the rarity of sarcomas and the complexity of diverse subtypes makes it challenging to investigate novel drug formulations. Experimental Design: New drug formulations can be tested in animal models of sarcomas where the therapeutic response of different formulations can be compared using mice with identical tumor-initiating mutations. Here, using Cre/loxP and CRISPR/Cas9 techniques, we generated two distinct mouse models of Pten-deleted soft-tissue sarcoma: malignant peripheral nerve sheath tumor (MPNST) and undifferentiated pleomorphic sarcoma (UPS). We used these models to test the efficacy of chimeric polypeptide doxorubicin (CP-Dox), a nanoscale micelle formulation, in comparison with free doxorubicin. Results: The CP-Dox formulation was superior to free doxorubicin in MPNST models. However, in UPS tumors, CP-Dox did not improve survival in comparison with free doxorubicin. While CP-Dox treatment resulted in elevated intratumoral doxorubicin concentrations in MPNSTs, this increase was absent in UPS tumors. In addition, elevation of CD8+ T cells was observed exclusively in CP-Dox–treated MPNSTs, although these cells were not required for full efficacy of the CP nanoparticle–based chemotherapy. Conclusions: These results have important implications for treating sarcomas with nanoparticle-encapsulated chemotherapy by highlighting the tumor subtype–dependent nature of therapeutic response.